In our present study, the missense mutation of LRP1B was detected in original cervical cancer, F2-PDX models and F3-PDX models, which may potentially become a new therapeutic target for cervical cancer patients, and further study will be needed to discover a novel and efficient targeted therapy. This evidence concerns the gene LRP1B and cervical carcinoma.